Ireland-based Endo International has signed an agreement to acquire Par Pharmaceutical Holdings from TPG for $8.05bn.
Under the deal, Par shareholders will receive $6.50bn in cash and 18 million shares worth $1.55bn.
Go deeper with GlobalData
TPG acquired Par Pharmaceutical through its affiliate under a take-private transaction in 2012.
Endo International president and CEO Rajiv De Silva said: "Our generics business, qualitest, continues to be an extremely attractive and effective growth driver for Endo.
"This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A."
The acquired business is said to expand Endo’s generics business, creating one of the top five businesses in this segment.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPar produces around 100 products in multiple dosage forms and delivery systems, including oral solids, oral suspensions, injectables and high barrier-to-entry products.
The company also offers a product pipeline, including more than 200 abbreviated new drug applications (ANDAs), with 115 filed with the US Food and Drug Administration (FDA) as of 31 December 2014.
Par Pharmaceutical CEO Campanelli said: "We share Endo’s goal of developing and commercialising generic drugs in areas of greatest revenue potential, complex formulations and longer lifecycles."
Subject to regulatory approval in the US and certain other jurisdictions, as well as other customary closing conditions, the deal is expected to complete in the second half of this year.
